21062

544067

INNOVACAP

img img img img
No Data Available

INNOVA CAPTAB LIMITED Share Price Update

As of the latest trading session, INNOVA CAPTAB LIMITED is trading at ₹877.2, up by ₹13.54 or 1.56% from its previous close. The stock has moved between ₹830.00 and ₹900.00 today. Over the past year, the stock has delivered a return of -1.34%. In the last month, it has returned 28.19%.

INNOVA CAPTAB LIMITED performance

Today’s low Today’s high
₹ 830.00 ₹ 900.00
₹ 875.75
52 week low 52 week high
₹ 622.00 ₹ 1020.70
₹ 875.75
Open Price ₹ 850.75
Prev. Close ₹ 863.65
Volume (Shares) 155822.00
Total traded value ₹ 1364.61
Upper Circuit ₹ 1036.35
Lower Circuit ₹ 690.95
info

Investment Returns

Over 1 Month 28.19% Over 3 Months 23.36% Over 6 Months 18.27% Over 1 Year -1.34%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

INNOVA CAPTAB LIMITED fundamentals


  • Market cap (Cr) 5,011.50
  • P/E Ratio (TTM) 59.84
  • Beta 0.74
  • Book Value / share 154.94
  • Return on equity 11.64%
  • EPS (TTM) 14.63
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 21.16
info icon alternate text
  • Market cap (Cr) 5,009.80
  • P/E Ratio (TTM) 59.84
  • Beta 0.71
  • Book Value / share 154.94
  • Return on equity 11.64%
  • EPS (TTM) 14.63
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 21.16
info icon alternate text

INNOVA CAPTAB LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 358.28
Operating Expense 333.02
Net Profit 21.16
Net Profit Margin (%) 5.90
Earnings Per Share (EPS) 3.70
EBITDA 41.32
Effective Tax Rate (%) 24.23
Particulars DEC 2025 (Values in Cr)
Revenue 363.73
Operating Expense 329.61
Net Profit 27.90
Net Profit Margin (%) 7.67
Earnings Per Share (EPS) 4.88
EBITDA 50.20
Effective Tax Rate (%) 25.26
Particulars SEP 2025 (Values in Cr)
Revenue 289.83
Operating Expense 275.20
Net Profit 14.33
Net Profit Margin (%) 4.94
Earnings Per Share (EPS) 2.50
EBITDA 33.96
Effective Tax Rate (%) 25.63
Particulars JUN 2025 (Values in Cr)
Revenue 286.98
Operating Expense 264.00
Net Profit 20.30
Net Profit Margin (%) 7.07
Earnings Per Share (EPS) 3.55
EBITDA 39.14
Effective Tax Rate (%) 25.65
Particulars MAR 2025 (Values in Cr)
Revenue 242.52
Operating Expense 224.02
Net Profit 17.13
Net Profit Margin (%) 7.06
Earnings Per Share (EPS) 2.99
EBITDA 32.54
Effective Tax Rate (%) 25.06
Particulars MAR 2026 (Values in Cr)
Revenue 1298.81
Operating Expense 1200.23
Net Profit 83.69
Net Profit Margin (%) 6.44
Earnings Per Share (EPS) 14.63
EBITDA 164.60
Effective Tax Rate (%) 25.15
Particulars MAR 2025 (Values in Cr)
Revenue 958.06
Operating Expense 854.94
Net Profit 89.47
Net Profit Margin (%) 9.33
Earnings Per Share (EPS) 15.63
EBITDA 139.08
Effective Tax Rate (%) 25.37
Particulars MAR 2024 (Values in Cr)
Revenue 864.93
Operating Expense 781.95
Net Profit 68.16
Net Profit Margin (%) 7.88
Earnings Per Share (EPS) 13.48
EBITDA 118.69
Effective Tax Rate (%) 27.25
Particulars MAR 2023 (Values in Cr)
Revenue 858.67
Operating Expense 789.09
Net Profit 57.55
Net Profit Margin (%) 6.70
Earnings Per Share (EPS) 11.99
EBITDA 107.27
Effective Tax Rate (%) 26.51
Particulars MAR 2022 (Values in Cr)
Revenue 785.46
Operating Expense 699.68
Net Profit 66.18
Net Profit Margin (%) 8.42
Earnings Per Share (EPS) 550.05
EBITDA 101.36
Effective Tax Rate (%) 25.34
Particulars MAR 2025 (Values in Cr)
Book Value / Share 167.66
ROE % 14.33
ROCE % 14.50
Total Debt to Total Equity 0.33
EBITDA Margin 15.94
Particulars MAR 2024 (Values in Cr)
Book Value / Share 145.20
ROE % 17.04
ROCE % 18.76
Total Debt to Total Equity 0.38
EBITDA Margin 15.44
Particulars MAR 2023 (Values in Cr)
Book Value / Share 57.61
ROE % 28.01
ROCE % 23.92
Total Debt to Total Equity 0.73
EBITDA Margin 13.26
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1738.38
ROE % 36.19
ROCE % 30.38
Total Debt to Total Equity 0.69
EBITDA Margin 12.35
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1206.84
ROE % 27.04
ROCE % 28.18
Total Debt to Total Equity 0.39
EBITDA Margin 13.60
Particulars MAR 2025 (Values in Cr)
Book Value / Share 142.06
ROE % 11.64
ROCE % 11.53
Total Debt to Total Equity 0.37
EBITDA Margin 14.52
Particulars MAR 2024 (Values in Cr)
Book Value / Share 126.47
ROE % 13.74
ROCE % 14.44
Total Debt to Total Equity 0.42
EBITDA Margin 13.72
Particulars MAR 2023 (Values in Cr)
Book Value / Share 55.90
ROE % 24.02
ROCE % 21.34
Total Debt to Total Equity 0.70
EBITDA Margin 12.49
Particulars MAR 2022 (Values in Cr)
Book Value / Share 175.69
ROE % 37.22
ROCE % 32.34
Total Debt to Total Equity 0.62
EBITDA Margin 12.91
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1206.84
ROE % 27.04
ROCE % 28.18
Total Debt to Total Equity 0.39
EBITDA Margin 13.60
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 68.16
Total Assets 1580.40
Total Liabilities 1580.40
Total Equity 959.41
Share Outstanding 5
Price to Book Ratio 6.18
Return on Assets (%) 8.11
Return on Capital (%) 9.9
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 86.74
Total Assets 1320.88
Total Liabilities 1320.88
Total Equity 830.89
Share Outstanding 5
Price to Book Ratio 3.54
Return on Assets (%) 7.14
Return on Capital (%) 8.8
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 18.87
Total Assets 704.41
Total Liabilities 704.41
Total Equity 276.50
Share Outstanding 4
Price to Book Ratio 0.00
Return on Assets (%) 9.64
Return on Capital (%) 13.28
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.43
Total Assets 575.47
Total Liabilities 575.47
Total Equity 208.60
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 11.11
Return on Capital (%) 15.72
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 11.89
Total Assets 369.61
Total Liabilities 369.61
Total Equity 144.82
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 9.33
Return on Capital (%) 18.17
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 67.89
Total Assets 1365.14
Total Liabilities 1365.14
Total Equity 812.96
Share Outstanding 5
Price to Book Ratio 6.18
Return on Assets (%) 6.55
Return on Capital (%) 7.85
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 86.35
Total Assets 1155.06
Total Liabilities 1155.06
Total Equity 723.71
Share Outstanding 5
Price to Book Ratio 3.54
Return on Assets (%) 5.90
Return on Capital (%) 7.07
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 14.98
Total Assets 678.33
Total Liabilities 678.33
Total Equity 268.32
Share Outstanding 4
Price to Book Ratio 0.00
Return on Assets (%) 8.48
Return on Capital (%) 11.43
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.18
Total Assets 544.91
Total Liabilities 544.91
Total Equity 210.82
Share Outstanding 1
Price to Book Ratio 0.00
Return on Assets (%) 12.14
Return on Capital (%) 17.11
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 11.89
Total Assets 369.61
Total Liabilities 369.61
Total Equity 144.82
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 9.33
Return on Capital (%) 18.17
Particulars MAR 2025 (Values in Cr)
Net Income 171.01
Cash from Operations 87.55
Cash from Investing -151.58
Cash from Financing 91.53
Net change in Cash 3.79
Free Cash Flow 260.05
Particulars MAR 2024 (Values in Cr)
Net Income 129.52
Cash from Operations 173.99
Cash from Investing -498.97
Cash from Financing 360.83
Net change in Cash 8.20
Free Cash Flow 461.35
Particulars MAR 2023 (Values in Cr)
Net Income 91.79
Cash from Operations 86.65
Cash from Investing -90.84
Cash from Financing 27.09
Net change in Cash 3.37
Free Cash Flow 165.64
Particulars MAR 2022 (Values in Cr)
Net Income 85.72
Cash from Operations 79.74
Cash from Investing -188.11
Cash from Financing 124.57
Net change in Cash -4.64
Free Cash Flow 159.62
Particulars MAR 2021 (Values in Cr)
Net Income 46.34
Cash from Operations 54.79
Cash from Investing -19.67
Cash from Financing -19.33
Net change in Cash 2.55
Free Cash Flow 73.53
Particulars MAR 2025 (Values in Cr)
Net Income 119.89
Cash from Operations 39.19
Cash from Investing -99.74
Cash from Financing 83.86
Net change in Cash 3.91
Free Cash Flow 200.12
Particulars MAR 2024 (Values in Cr)
Net Income 93.69
Cash from Operations 135.66
Cash from Investing -471.55
Cash from Financing 368.13
Net change in Cash 8.25
Free Cash Flow 412.89
Particulars MAR 2023 (Values in Cr)
Net Income 78.30
Cash from Operations 58.18
Cash from Investing -87.53
Cash from Financing 51.28
Net change in Cash 3.03
Free Cash Flow 137.07
Particulars MAR 2022 (Values in Cr)
Net Income 88.63
Cash from Operations 79.25
Cash from Investing -188.33
Cash from Financing 125.29
Net change in Cash -4.69
Free Cash Flow 159.12
Particulars MAR 2021 (Values in Cr)
Net Income 46.34
Cash from Operations 54.94
Cash from Investing -19.67
Cash from Financing -19.33
Net change in Cash 2.56
Free Cash Flow 73.68
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 33.09 14.32 1.71 253.58 23.12 40.44
BLISS GVS PHARMA LTD. 269.35 25.75 2.51 2849.43 105.05 280.20
CIPLA LTD 1347.70 22.90 3.30 108864.87 1165.55 1672.20
FERMENTA BIOTECH LTD. 288.70 9.60 2.17 849.67 252.15 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 33.09 31.82 4.61 253.58 23.12 40.44
AMRUTANJAN HEALTH CARE LTD. 548.80 27.44 4.63 1586.62 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8489.25 102.02 26.56 21223.13 7630.00 10653.05
BLISS GVS PHARMA LTD. 269.35 36.70 2.58 2849.43 105.05 280.20

INNOVA CAPTAB LIMITED shareholding pattern

Holding
28.73%
50.89%
0.23%
20.13%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

INNOVA CAPTAB LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
875.75 1.40 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 850.70
  • 26 Days 761.90
  • 10 Days 815.60
  • 50 Days 735.30
  • 12 Days 805.00
  • 100 Days 730.80
  • 20 Days 775.60
  • 200 Days 752.30
866.93 PIVOT
First Support 849.87 First Resistance 880.72 Second Support 836.08 Second Resistance 897.78 Third Support 819.02 Third Resistance 911.57
RSI 78.35 ADX 30.80 MACD 43.03 Williams % R -12.27 Commodity Channel Index (CCI) 142.00
Date 2026-05-08 Week 76461.00 Same Day 70444.00 Month 57813.00
1 Year 0.75 3 Year 0.87
Over 1 Month
28.19% down
Over 1 Year
-1.34% down
Over 3 Months
23.36% down
Over 3 Years
17.38% down
Over 6 Months
18.27% down
Over 5 Years
0.00% down

INNOVA CAPTAB LIMITED Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
30 Jan 2026 2.0 Interim 30 Jan 2026 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
30 Jan 2026 2.0 Interim 30 Jan 2026 Equity shares

Top Gainers

Top Losers

INNOVA CAPTAB LIMITED Share Price

Innova Captab Limited was incorporated as Harun Health Care Private Limited', dated January 3, 2005, as a Private Limited Company at Mumbai. Thereafter, the name of the Company was changed from Harun Health Care Private Limited' to Innova Captab Private Limited', and a fresh Certificate of Incorporation dated February 2, 2010, was issued by RoC to the Company. Subsequently, Company got converted to a Public Company on July 12, 2018, and the name was changed to Innova Captab Limited', dated July 26, 2018.

The Company is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Their business includes contract development and manufacturing organization (CDMO) business providing manufacturing services to Indian pharmaceutical companies, domestic branded generics business and an international branded generics business.

Their CDMO product portfolio spans across both acute and chronic therapeutic areas. These CDMO services and products include commercial large-scale manufacturing of generic products, which allow customers in offering multiple dosage forms, including oral solids, oral liquids, dry syrups and injectables, modified and release forms of tablets in capsules. It has 2 manufacturing facilities in Baddi, Himachal Pradesh. Their facilities further produce tablets, capsules, dry syrups, dry powder injections, ointments and liquid orals.

In 2006, the first manufacturing plant got established in Baddi, at Himachal Pradesh.

In 2010, it commenced operations at the cephalosporin block of their plant in Baddi.

In 2021, the Company acquired business of Innova Captab, a Partnership Firm, as a going concern through Slump Sale effective in March, 2021 and acquired Univentis Medicare Limited (UML) 100% equity shares effective on December 31, 2021 and consequently, The Univentis Foundation became a Subsidiary of Company on June 14, 2021.

The Company commenced construction to establish an industrial plant in Jammu and Kashmir and to build an R&D center in Panchkula, Haryana in 2022.

In December 2023, the Company came up with an IPO aggregating to Rs 570 Crores by issuing 12,723,214 Equity Shares, comprising 7,142,857 Equity Shares aggregating to Rs 320 Crore through Fresh Issue and 5,580,357 Equity Shares aggregating to Rs 250 Crore through Offer for Sale.

The Company acquired Sharon Bio-Medicine Limited in June, 2023. In 2024-25, Company commissioned a new greenfield facility in Kathua, Jammu w.e.f. 14 January, 2025.

Parent organization Indian Private
NSE symbol INNOVACAP
Founded 2005
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Innova Captab Ltd?

Answer Field

Innova Captab Ltd share price is for NSE ₹ 877.20 & for BSE ₹ 875.40 as on May 08 2026 03:29 PM.

What is the Market Cap of Innova Captab Ltd Share?

Answer Field

The market cap of Innova Captab Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on May 08 2026 03:29 PM.

What is the 52 Week High and Low of Innova Captab Ltd?

Answer Field

The 52 Week High and Low of Innova Captab Ltd for NSE is ₹ 1,020.70 and ₹ 622.00 and for BSE is ₹ 1,002.95 and ₹ 608.25.

What is 1 year return for Innova Captab Ltd?

Answer Field

The 1 year returns on the stock has been -1.34%.

What is the P/E Ratio of Innova Captab Ltd Share?

Answer Field

As on May 08 2026 03:29 PM the price-to-earnings (PE) ratio for Innova Captab Ltd share is 59.84.

What is the PB ratio of Innova Captab Ltd Share?

Answer Field

As on May 08 2026 03:29 PM, the price-to-book (PB) ratio for Innova Captab Ltd share is 154.94.

How to Buy Innova Captab Ltd Share?

Answer Field

You can trade in Innova Captab Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Innova Captab Ltd Share on Bajaj Broking App?

Answer Field

To buy Innova Captab Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Innova Captab Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|